
The generic versions of the drug would not only aid manufacturing, but they would probably be cheaper. In early deals made with the United States, Merck sold molnupiravir for $712 a treatment course, Pfizer sold Paxlovid for $530. Brook Baker, a professor of law at Northeastern University who tracks pharmaceutical deals, estimates generics of molnupiravir could be sold for as little as $10 per treatment.
The Washington Post: Breaking News, World, US, DC News and Analysis
0 Comments